873 related articles for article (PubMed ID: 34172516)
1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Galsky MD; Balar AV; Black PC; Campbell MT; Dykstra GS; Grivas P; Gupta S; Hoimes CJ; Lopez LP; Meeks JJ; Plimack ER; Rosenberg JE; Shore N; Steinberg GD; Kamat AM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266883
[TBL] [Abstract][Full Text] [Related]
3. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
4. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Neelapu SS; Adkins S; Ansell SM; Brody J; Cairo MS; Friedberg JW; Kline JP; Levy R; Porter DL; van Besien K; Werner M; Bishop MR
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361336
[TBL] [Abstract][Full Text] [Related]
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Maus MV; Alexander S; Bishop MR; Brudno JN; Callahan C; Davila ML; Diamonte C; Dietrich J; Fitzgerald JC; Frigault MJ; Fry TJ; Holter-Chakrabarty JL; Komanduri KV; Lee DW; Locke FL; Maude SL; McCarthy PL; Mead E; Neelapu SS; Neilan TG; Santomasso BD; Shpall EJ; Teachey DT; Turtle CJ; Whitehead T; Grupp SA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335028
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
9. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
Kluger H; Barrett JC; Gainor JF; Hamid O; Hurwitz M; LaVallee T; Moss RA; Zappasodi R; Sullivan RJ; Tawbi H; Sharon E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918224
[TBL] [Abstract][Full Text] [Related]
10. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
11. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
12. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
14. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
15. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
16. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
17. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
18. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
Choi J; Anderson R; Blidner A; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Lacouture ME
Support Care Cancer; 2020 Dec; 28(12):6119-6128. PubMed ID: 32856211
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
20. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]